Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging - Defined locally advanced rectal cancer: Impact on long-term clinical outcomes

Journal of Clinical Oncology

Volumn 29, Issue 8, 2011, Pages 1042-1049

  Gollins, Simon ^a   Myint, Arthur Sun ^a   Haylock, Brian ^a   Wise, Marcus ^a   Saunders, Mark ^a   Neupane, Rekha ^a   Essapen, Sharadah ^a   Samuel, Les ^a   Dougal, Mark ^a   Lloyd, Arwel ^a   Morris, Jackie ^a   Topham, Clare ^a   Susnerwala, Shabbir ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HISTOLOGY; HUMAN; LETHARGY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PELVIS; PHASE 2 CLINICAL TRIAL; PREDICTION; PREOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE FRACTIONATION; RECTUM CARCINOMA; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GREAT BRITAIN; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RADIATION DOSAGE; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952752534     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.7697     Document Type: Article

References (44)

1. Nagtegaal ID, Marijnen CA, Kranenbarg EK, et al: Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: Not one millimetre but two millimetres is the limit. Am J Surg Pathol 26:350-357, 2002 (Pubitemid 34184459)
2. Marijnen CAM, Nagtegaal ID, Kapiteijn E, et al: Radiotherapy does not compensate for positive resection margins in rectal cancer patients: Report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys 55:1311-1320, 2003 (Pubitemid 36338299)
3. Mawdsley S, Glynne-Jones R, Grainger J, et al: Can histopathologic assessment of circumferential resection margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival? Int J Radiat Oncol Biol Phys 63:745-752, 2005
4. Nagtegaal ID, Quirke P: What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 26:303-312, 2008
5. MacFarlane JK, Ryall RDH, Heald RJ: Mesorectal excision for rectal cancer. Lancet 341:457-460, 1993 (Pubitemid 23054519)
6. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638-646, 2001
7. Sebag-Montefiore D, Stephens RJ, Steele R, et al: Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCI CCTG C016): A multicentre, randomised trial. Lancet 373:811-820, 2009
8. Quirke P, Steele R, Monson J, et al: Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: A prospective study using data from the MRC CR07 and NCIC-CTG C016 randomised clinical trial. Lancet 373:821-828, 2009
9. Colorectal Cancer Collaborative Group: Adjuvant radiotherapy for rectal cancer: A systematic overview of 8,507 patients from 22 randomised trials. Lancet 358:1291-1304, 2001
10. Gerard J-P, Conroy T, Bonnetain F, et al: Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203. J Clin Oncol 24:4620-4625, 2006 (Pubitemid 46630960)
11. Bosset J-F, Collette L, Calais G, et al: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114-1123, 2006 (Pubitemid 44394918)
12. Sauer R, Becker H, Hohenberger W, et al: Preoperative versus postoperative radiotherapy for rectal cancer. N Engl J Med 351:1731-1740, 2004
13. MERCURY Study Group Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: Prospective observational study. BMJ 333:779-782, 2006
14. Sanghera P, Wong DWY, McConkey CC, et al: Chemoradiotherapy for rectal cancer: An updated analysis of factors affecting pathological response. Clin Oncol 20:176-183, 2008
15. Mehta VK, Cho C, Ford JM, et al: Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys 55:132-137, 2003 (Pubitemid 36020352)
16. Klautke G, Feyerherd P, Ludwig K, et al: Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer. Br J Cancer 92:1215-1220, 2005 (Pubitemid 40604394)
17. Navarro M, Dotor E, Rivera F, et al: A phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-flourouracil, for resectable locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 66:201-205, 2006 (Pubitemid 44175647)
18. Mohiuddin M, Winter K, Mitchell E, et al: Randomized phase II study of neoadjuvant combinedmodality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group trial 0012. J Clin Oncol 2006 24:650-655, 2006
19. Glynne-Jones R, Falk S, Maughan TS, et al: A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: A Colorectal Clinical Oncology Group study. Br J Cancer 96:551-558, 2007
20. Iles SM, Gollins SW, Susnerwala S, et al: Irinotecan + 5-fluorouracil with concomitant preoperative radiotherapy in locally advanced nonresectable rectal cancer: A phase I/II study. Br J Cancer 98:1210-1216, 2008 (Pubitemid 351481677)
21. Klautke G, Kuchenmeister U, Foitzik T, et al: Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: Results from a phase I/II study. Br J Cancer 94:976-981, 2006
22. Klautke G, Kuchenmeister U, Foitzik T, et al: Intensified irinotecan-based neoadjuvant chemotherapy in rectal cancer: Four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by complete pathological response. Rad Oncol 85:379-384, 2007 (Pubitemid 350218177)
23. Willeke F, Horisberger K, Kraus-Tiefenbacher U, et al: A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer 96:912-917, 2007 (Pubitemid 46452282)
24. Gollins SW, Myint S, Susnerwala S, et al: Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: A phase I trial (NWCOG-2). Br J Cancer 101:924-934, 2009
25. Quirke P, Williams GT: Minimum Dataset for Colorectal Cancer Histopathology Reports. London, United Kingdom, Royal College of Pathologists, 1998
26. Francois Y, Nemoz CJ, Baulieux J, et al: Influence of the Interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: The Lyon R90-01 randomized trial. J Clin Oncol 17:2396-2402, 1999 (Pubitemid 29368238)
27. Salerno GV, Daniels IR, Moran BJ, et al: Magnetic resonance imaging prediction of an involved surgical resection margin in low rectal cancer. Dis Colon Rectum 52:632-639, 2009
28. Lahaye MJ, Engelen SM, Nelemans PJ, et al: Imaging for predicting the risk factors - the circumferential resection margin and nodal disease - of local recurrence in rectal cancer: A meta-analysis. Semin Ultrasound CT MR 26:259-268, 2005 (Pubitemid 41111583)
29. MERCURY Study Group: Extramural depth of tumour invasion at thin-section MR in patients with rectal cancer: Results of the MERCURY Study. Radiology 243:132-139, 2007
30. Kauer WK, Prantl L, Dittler HJ, et al: The value of endosonographic rectal carcinoma staging in routine diagnostics: A 10-year analysis. Surg Endosc 18:1075-1078, 2004 (Pubitemid 38918019)
31. Guillem JG, Diaz-Gonzalez JA, Minsky BD, et al: CT3N0 rectal cancer: Potential overtreatment with chemoradiotherapy is warranted. J Clin Oncol 26:368-373, 2008 (Pubitemid 351171686)
32. Wang C, Zongguang Z, Wang Z, et al: Patterns of neoplastic foci and micrometastasis within the mesorectum. Langenbeck's Arch Surg 390:312-318, 2005 (Pubitemid 41110975)
33. West N, Grabsch H, Treanor D, et al: Quantitative assessment of tumor cell density in rectal cancer following three different preoperative therapies compared to surgery alone. J Clin Oncol 28:298s, 2010 (suppl; abstr 3651)
34. Kaminsky-Forret M-C, Conroy T, Luporsi E, et al: Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancer. Int J Radiat Oncol Biol Phys 42:935-941, 1998 (Pubitemid 29004132)
35. Mohiuddin M, Hayne M, Regine WF, et al: Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Radiat Oncol Biol Phys 48:1075-1080, 2000
36. Valentini V, Coco C, Picciocchi A, et al: Does downstaging predict improved outcome after preoperative chmoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys 53:664-674, 2002 (Pubitemid 34626505)
37. Vecchio FM, Valentini V, Minsky B, et al: The relationship of pathologic tumour regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys 62:752-760, 2005 (Pubitemid 40779765)
38. Chapet O, Romestaing P, Mornex F, et al: Preoperative radiotherapy for rectal adenocarcinoma: Which are strong prognostic factors? Int J Radiat Oncol Biol Phys 61:1371-1377, 2005
39. Rodel C, Martus P, Papadoupolos T, et al: Prognostic significance of tumour regression after preoperative radiotherapy for rectal cancer. J Clin Oncol 23:8688-8696, 2005 (Pubitemid 46211512)
40. Roh MS, Colangelo LH, O'Connell MJ, et al: Preoperative multimodality therapy improves diseasefree survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 27:5124-5130, 2009
41. Collette L, Bossett J-F, den Dulk M, et al: Patients with curative resection of cT3-T4 rectal cancer after preoperative radiochemotherapy: Does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial from the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 25:4379-4386, 2007 (Pubitemid 350013843)
42. Aschele C, Pinto C, Rosati G, et al: Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial. J Clin Oncol 27:804s, 2009 (suppl; abstr CRA4008)
43. Gerard JP, Azria D, Gourgou-Bourgade S, et al: Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: Results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28:1638-1644, 2010
44. Glynne-Jones R, Sebag-Montefiore D: Are we ready to use an early alternative end point as the primary end point of a phase III study in rectal cancer? J Clin Oncol 28:e579-e580, 2010